Lilly Marks Zosano's Second Pharma Partner Loss
This article was originally published in Scrip
Executive Summary
Zosano Pharma Corp. is trading at a fraction of its initial public offering price after the transdermal drug developer revealed that it has parted ways with Eli Lilly & Co. – the second big pharma partnership that the company has lost this year.